{"id":15141,"date":"2022-02-17T10:51:16","date_gmt":"2022-02-17T09:51:16","guid":{"rendered":"http:\/\/miunidad.eu\/porib.com\/?p=15141"},"modified":"2022-03-11T10:54:04","modified_gmt":"2022-03-11T09:54:04","slug":"axicabtagen-ciloleucel-una-alternativa-coste-efectiva-en-el-tratamiento-del-linfoma-b-difuso-de-celulas-grandes","status":"publish","type":"post","link":"https:\/\/porib.com\/en\/axicabtagen-ciloleucel-una-alternativa-coste-efectiva-en-el-tratamiento-del-linfoma-b-difuso-de-celulas-grandes\/","title":{"rendered":"Axicabtag\u00e9n ciloleucel, una alternativa coste-efectiva en el tratamiento del linfoma B difuso de c\u00e9lulas grandes"},"content":{"rendered":"

La terapia CAR-T, axicabtag\u00e9n ciloleucel (Yescarta\u00ae), ha demostrado ser una terapia eficiente frente a tisagenlecleucel (Kymriah\u00ae) en el tratamiento de pacientes con linfoma B difuso de c\u00e9lulas grandes en reca\u00edda y\/o refractario despu\u00e9s de dos o m\u00e1s l\u00edneas de tratamiento sist\u00e9mico. De acuerdo con los resultados alcanzados, axicabtag\u00e9n ciloleucel lograr\u00eda prolongar la supervivencia en t\u00e9rminos de a\u00f1os de vida ganados y una mejora en la calidad de vida en comparaci\u00f3n con tisagenlecleucel.<\/p>\n

Estos resultados han sido presentados en el art\u00edculo publicado en la revista Cancers<\/em>, \u201cCost-Effectiveness Analysis of Axicabtagene Ciloleucel vs Tisagenlecleucel for the Management of Relapsed\/Refractory Diffuse Large B-Cell Lymphoma in Spain\u201c<\/em><\/strong> de los autores Bastos-Oreiro M, de las Heras A, Presa M, Casado MA, Pardo C, Mart\u00edn-Escudero V, Sureda A.<\/p>\n","protected":false},"excerpt":{"rendered":"

La terapia CAR-T, axicabtag\u00e9n ciloleucel (Yescarta\u00ae), ha demostrado ser una terapia eficiente frente a tisagenlecleucel (Kymriah\u00ae) en el tratamiento de pacientes con linfoma B difuso de c\u00e9lulas grandes en reca\u00edda y\/o refractario despu\u00e9s de dos o m\u00e1s l\u00edneas de tratamiento sist\u00e9mico. De acuerdo con los resultados alcanzados, axicabtag\u00e9n ciloleucel lograr\u00eda prolongar la supervivencia en t\u00e9rminos… <\/p>\n

<\/div>\n

Read More<\/i><\/a><\/p>\n","protected":false},"author":4,"featured_media":15142,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[67],"tags":[],"class_list":["post-15141","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ultimas-noticias"],"translation":{"provider":"WPGlobus","version":"2.10.3","language":"en","enabled_languages":["es","en"],"languages":{"es":{"title":true,"content":true,"excerpt":false},"en":{"title":false,"content":false,"excerpt":false}}},"_links":{"self":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts\/15141"}],"collection":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/comments?post=15141"}],"version-history":[{"count":1,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts\/15141\/revisions"}],"predecessor-version":[{"id":15143,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts\/15141\/revisions\/15143"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/media\/15142"}],"wp:attachment":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/media?parent=15141"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/categories?post=15141"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/tags?post=15141"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}